First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study

International Journal of Clinical Oncology

Volumn 20, Issue 5, 2015, Pages 952-959

  Liu, Ying ^a   Yue, Han ^b   Xu, Shuning ^a   Wang, Feng ^c   Ma, Ning ^b   Li, Ke ^a   Qiao, Lei ^a   Wang, Jufeng ^a  

^a ZHENGZHOU UNIVERSITY   (China)

^b HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

Chemotherapy; Gemcitabine; Hepatocellular carcinoma; Oxaliplatin; Sorafenib

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GEMCITABINE; OXALIPLATIN; SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; DEOXYCYTIDINE; NICOTINAMIDE; PLATINUM COMPLEX;

ACUTE HEART INFARCTION; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER PATIENT; CLINICAL ARTICLE; DESQUAMATION; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; INVESTIGATIVE PROCEDURES; LIVER CELL CARCINOMA; LOSS OF APPETITE; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RASH; SIDE EFFECT; SINGLE BLIND PROCEDURE; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; LIVER NEOPLASMS; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; DEOXYCYTIDINE; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; ORGANOPLATINUM COMPOUNDS; PHENYLUREA COMPOUNDS; PROSPECTIVE STUDIES;

EID: 84942987178     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-015-0796-5     Document Type: Article

References (28)

1. Parkin DM, Bray F, Ferlay J (2005) Global cancer statistics 2002. Cancer J Clin 55:74–108
2. Hung H (2005) Treatment modalities for hepatocellular carcinoma. Curr Cancer Drug Targets 5:131–138
3. Hsu C, Shen YC, Cheng CC (2010) Geographic difference in survival outcome for advanced hepatocellular carcinoma: implications on future clinical trial design. Contemp Clin Trials 31:55–61
4. 2) for hepatocellular carcinoma: clinical and pharmacokinetic results. Cancer Treat Rep 68:487–491
5. Falkson G, Ryan LM, Johnson LA (1987) A random phase II study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma. An ECOG study. Cancer 60:2141–2145
6. Hebbar M, Ernst O, Cattan S (2006) Phase II trial of docetaxel therapy in patients with advanced hepatocellular carcinoma. Oncology 70:154–158
7. Boige V, Taieb J, Hebbar M (2006) Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin level. Eur J Cancer 42:456–459
8. Guan Z, Wang Y, Maoleekoonpairoj S (2003) Prospective randomized phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma. Br J Cancer 89:1865–1869
9. Llovet JM, Ruff P, Tassopoulos N (2001) A phase II trial of oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma. Eur J Cancer 37:1352–1358
10. Wilhelm SM, Carter C, Tang L (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099–7109
11. Iyer R, Fetterly G, Lugade A (2010) Sorafenib: a clinical and pharmacologic review. Expert Opin Pharmacother 11:1943–1955
12. Chang YS, Adnane J, Trail PA (2007) Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 59:561–574
13. Llovet JM, Ricci S, Mazzaferro V, SHARP Investigators Study Group (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390
14. Abou-Alfa GK, Johnson P, Knox JJ (2010) Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 304:2154–2160
15. Srimuninnimit V, Sriuranpong V, Suwanvecho S (2014) Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: a multicenter, open-label, single-arm phase II study. Asia Pac J Clin Oncol 10:255–260
16. Zaanan A, Williet N, Hebbar M (2013) Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study. J Hepatol 58:81–88
17. Llovet JM, Brú C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19(3):329–338
18. Therasse P, Arbuck SG, Eisenhauer EA (2000) New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the US, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216
19. The Criteria Committee of the New York Heart Association (1994) Nomenclature and criteria for diagnosis of diseases of the heart and great vessels, 9th edn. Little Brown, Boston, pp 253–256
20. Grothey A (2005) Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer 5(1):S38–S46
21. Lee SJ, Lee J, Park SH (2012) Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma. Invest New Drugs 30:1540–1547
22. Ooka Y, Chiba T, Ogasawara S et al (2014) a phase I/II study of S-1 with sorafenib in patients with advanced hepatocellular carcinoma. Invest New Drugs 32(4):723–728
23. Hsu CH, Kang YK, Yang TS et al (2013) Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: a multicenter phase II study. Oncology 85(1):44–52
24. Kaseb AO, Garrett-Mayer E, Morris JS et al (2012) Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial. Oncology 82(2):67–74
25. Ikeda M, Shiina S, Nakachi K et al (2014) Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma. Invest New Drugs (Epub ahead of print)
26. Synold TW, Takimoto CH, Doroshow JH, National Cancer Institute Organ Dysfunction Working Group et al (2007) Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res 13(12):3660–3666
27. Ji YX, Zhang ZF, Lan KT et al (2014) Sorafenib in liver function impaired advanced hepatocellular carcinoma. Chin Med Sci J 29(1):7–14
28. Venook AP, Egorin MJ, Rosner GL et al (2000) Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: cancer and leukemia group B 9565. J Clin Oncol 18(14):2780–2787